{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:09:03Z","timestamp":1789175343214,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11606-026-10563-8","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:48:34Z","timestamp":1782316114000},"page":"3508-3515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statin-Related Myotoxicity: A Narrative Review and Practical Approach for General Internists"],"prefix":"10.1007","volume":"41","author":[{"given":"Isaac KS","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin SH","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson GW","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Thong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Feng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond B.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4688-7829","authenticated-orcid":false,"given":"Anselm","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"10563_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jamacardio.2023.0228","volume":"8","author":"JA Jacobs","year":"2023","unstructured":"Jacobs JA, Addo DK, Zheutlin AR, et al. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol. 2023;8:443\u2013452.","journal-title":"JAMA Cardiol"},{"key":"10563_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/clc.22577","volume":"39","author":"D Adedinsewo","year":"2016","unstructured":"Adedinsewo D, Taka N, Agasthi P, et al. Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011\u20132012. Clin Cardiol. 2016;39:491\u2013496.","journal-title":"Clin Cardiol"},{"key":"10563_CR3","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"CB Newman","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events A Scientific Statement from the American Heart Association. Arterioscler Thromb Vasc\u00a0Biol. 2019;39:E38\u2013E81.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10563_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jcm9010022","volume":"9","author":"RM Turner","year":"2020","unstructured":"Turner RM, Pirmohamed M. Statin-related myotoxicity: A comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2020;9:22.","journal-title":"J Clin Med"},{"key":"10563_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1186\/s12933-025-03003-0","volume":"24","author":"KC Sung","year":"2025","unstructured":"Sung KC, Kang D, Lee J, et al. Cardiovascular outcomes associated with incident diabetes during statin therapy: a nationwide propensity-matched cohort study. Cardiovasc Diabetol. 2025;24:460.","journal-title":"Cardiovasc Diabetol"},{"key":"10563_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.hjc.2019.09.001","volume":"61","author":"LS Rallidis","year":"2020","unstructured":"Rallidis LS. A practical algorithm for the management of patients with statin-associated muscle symptoms. Hell J Cardiol. 2020;61:137\u2013140.","journal-title":"Hellenic Journal of Cardiology"},{"key":"10563_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/clpt.2014.121","volume":"96","author":"A Alfirevic","year":"2014","unstructured":"Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014;96:470\u2013476.","journal-title":"Clin Pharmacol Ther"},{"key":"10563_CR8","doi-asserted-by":"crossref","unstructured":"Selva-O\u2019Callaghan A, Alvarado-Cardenas M, Pinal-Fern\u00e1ndez I, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018;14:215\u2013224.","DOI":"10.1080\/1744666X.2018.1440206"},{"key":"10563_CR9","doi-asserted-by":"publisher","unstructured":"Santulli G. Statins, skeletal muscle, and ryanodine receptor activation: resolving a 30-year mystery behind statin myotoxicity. Cardiovascular Diabetology \u2013 Endocrinology Reports. 2025;11:51. https:\/\/doi.org\/10.1186\/s40842-025-00267-z.","DOI":"10.1186\/s40842-025-00267-z"},{"key":"10563_CR10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMra1515161","volume":"374","author":"AL Mammen","year":"2016","unstructured":"Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med. 2016;374:664\u2013669.","journal-title":"New England Journal of Medicine"},{"key":"10563_CR11","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","volume":"67","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, Panza G, Zaleski A, et al. Statin-Associated Side Effects. JACC. 2016;67:2395\u20132410.","journal-title":"JACC"},{"key":"10563_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaccas.2019.12.019","volume":"2","author":"B Gawey","year":"2020","unstructured":"Gawey B, Tannu M, Rim J, et al. Statin-Induced Necrotizing Autoimmune\u00a0Myopathy. JACC Case Rep. 2020;2:440\u2013443.","journal-title":"JACC Case Rep"},{"key":"10563_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/TCRM.S197941","volume":"16","author":"E Tiniakou","year":"2020","unstructured":"Tiniakou E. Statin-associated autoimmune myopathy: Current perspectives. Ther Clin Risk Manag. 2020;16:483\u2013492.","journal-title":"Ther Clin Risk Manag"},{"key":"10563_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3988\/jcn.2022.18.4.489","volume":"18","author":"M Kang","year":"2022","unstructured":"Kang M, Park YE, Shin JH, et al. Statin-Induced Immune-Mediated Necrotizing Myopathy Does Not Always Present With Immediate or Severe Symptoms. J Clin Neurol (Korea). 2022;18:489\u2013491.","journal-title":"Journal of Clinical Neurology (Korea)"},{"key":"10563_CR15","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1093\/rheumatology\/keaf238","volume":"64","author":"T Khoo","year":"2025","unstructured":"Khoo T, Tan E, Limaye V, et al. The incidence of anti-HMGCR immune-mediated necrotizing myopathy: an Australian and UK retrospective multi-site cohort study. Rheumatol. 2025;64:4995\u20135003.","journal-title":"Rheumatology"},{"key":"10563_CR16","unstructured":"Agency for Care Effectiveness. Lipid management: focus on cardiovascular risk ACG. Singapore, https:\/\/isomer-user-content.by.gov.sg\/68\/3892784c-70b6-4e24-bb2a-7dd30d13e5f2\/Lipid%20management-%20focus%20on%20cardiovascular%20risk%20ACG%20(Dec%202023)%20v1.1.pdf. 2023, Accessed 25 Apr 2026."},{"key":"10563_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jcm9010022","volume":"9","author":"RM Turner","year":"2019","unstructured":"Turner RM, Pirmohamed M. Statin-related myotoxicity: A comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019;9:22.","journal-title":"J Clin Med"},{"key":"10563_CR18","doi-asserted-by":"crossref","unstructured":"Kellick KA, Bottorff M, Toth PP. A clinician\u2019s guide to statin drug-drug interactions. J Clin Lipidol. 2014;8:S30\u2013S46.","DOI":"10.1016\/j.jacl.2014.02.010"},{"key":"10563_CR19","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients with Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circ. 2016;134:e468\u2013e495.","journal-title":"Circulation"},{"key":"10563_CR20","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","volume":"26","author":"CW Holtzman","year":"2006","unstructured":"Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacother. 2006;26:1601\u20131607.","journal-title":"Pharmacotherapy"},{"key":"10563_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.amjmed.2015.07.036","volume":"129","author":"J Lee","year":"2016","unstructured":"Lee J, Morris J, Wald N. Grapefruit Juice and Statins. Am J Med. 2016;129:26\u201329.","journal-title":"Am J Med"},{"key":"10563_CR22","volume":"25","author":"C Ramasinghe","year":"2026","unstructured":"Ramasinghe C, Xu B. New insight into occurrence, quantification and bioactivities of lovastatin from natural resources (mushroom, red yeast rice and tea). J Agric Food Res. 2026;25:102621.","journal-title":"J Agric Food Res"},{"key":"10563_CR23","doi-asserted-by":"crossref","unstructured":"Cauchi J, Perez-Rosendahl M, Mozaffar T. Acute Necrotizing Myositis in Systemic Lupus Erythematous. Neurol. 2020;94 (15_supplement): 4816.","DOI":"10.1212\/WNL.94.15_supplement.4816"},{"key":"10563_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/DHPS.S333738","volume":"13","author":"N Safitri","year":"2021","unstructured":"Safitri N, Alaina MF, Pitaloka DAE, et al. A narrative review of statin-induced rhabdomyolysis: Molecular mechanism, risk factors, and management. Drug Healthc Patient Saf. 2021;13:211\u2013219.","journal-title":"Drug Healthc Patient Saf"},{"key":"10563_CR25","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","volume":"46","author":"PD Thompson","year":"1997","unstructured":"Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin Increases Exercise-Induced Skeletal Muscle Injury. Metab. 1997;46:1206\u20131210.","journal-title":"Metabolism"},{"key":"10563_CR26","doi-asserted-by":"crossref","unstructured":"John J. Grading of muscle power: comparison of MRC and analogue scales by physiotherapists. Medical Research Council. Int J Rehabil Res. 1984;7:173\u2013181.","DOI":"10.1097\/00004356-198406000-00005"},{"key":"10563_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","volume":"31","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Miller K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovasc Drugs Ther. 2017;31:179\u2013186.","journal-title":"Cardiovasc Drugs Ther"},{"key":"10563_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.14218\/JCTH.2021.00271","volume":"10","author":"LD Averbukh","year":"2022","unstructured":"Averbukh LD, Turshudzhyan A, Wu DC, et al. Statin-induced Liver Injury Patterns: A Clinical Review. J Clin Transl Hepatol. 2022;10:543\u2013552.","journal-title":"J Clin Transl Hepatol"},{"key":"10563_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3233\/JND-170282","volume":"5","author":"P Mohassel","year":"2018","unstructured":"Mohassel P, Mammen AL. Anti-HMGCR Myopathy. J Neuromuscul Dis. 2018;5:11\u201320.","journal-title":"Anti-HMGCR Myopathy. J Neuromuscul Dis"},{"key":"10563_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fneur.2016.00064","volume":"7","author":"A Malik","year":"2016","unstructured":"Malik A, Hayat G, Kalia JS, et al. Idiopathic inflammatory myopathies: Clinical approach and management. Front Neurol. 2016;7:64.","journal-title":"Front Neurol"},{"key":"10563_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul Disord. 2018;28:87\u201399.","journal-title":"Neuromuscular Disorders"},{"key":"10563_CR32","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","volume":"19","author":"AGS Oldroyd","year":"2023","unstructured":"Oldroyd AGS, Callen JP, Chinoy H, et al. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies\u00a0Group (IMACS)\u00a0initiative. Nat Rev Rheumatol. 2023;19:805\u2013817.","journal-title":"Nat Rev Rheumatol"},{"key":"10563_CR33","doi-asserted-by":"crossref","unstructured":"St\u00fcrzebecher PE, Schneider T, Gouni-Berthold I, et al. One-year treatment trajectories of patients with statin intolerance: results from a multicentre registry. Eur J Prev Cardiol. 2025;zwaf619.","DOI":"10.1093\/eurjpc\/zwaf619"},{"key":"10563_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","volume":"17","author":"BA Warden","year":"2023","unstructured":"Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17:19\u201339.","journal-title":"J Clin Lipidol"},{"key":"10563_CR35","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3949\/ccjm.70.9.777","volume":"70","author":"R Neal","year":"2003","unstructured":"Neal R, Jones P. Lipid-lowering: Can ezetimibe help close the treatment gap? Cleve Clin J Med. 2003;70:777\u2013783.","journal-title":"Cleve Clin J Med"},{"key":"10563_CR36","doi-asserted-by":"publisher","first-page":"1339487","DOI":"10.3389\/fcvm.2024.1339487","volume":"11","author":"I Mercep","year":"2024","unstructured":"Mercep I, Strikic D, Hrabac P, et al. PCSK9 inhibition: from effectiveness to cost-effectiveness. Front Cardiovasc Med. 2024;11:1339487.","journal-title":"Front Cardiovasc Med"},{"key":"10563_CR37","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1093\/jac\/dkw157","volume":"71","author":"J Maertens","year":"2016","unstructured":"Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother.\u00a02016; 71: 2397\u20132404.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10563_CR38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012\u20131022.","journal-title":"Aetiology and Management. Eur Heart J"},{"key":"10563_CR39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/phar.2674","volume":"42","author":"NC Schwier","year":"2022","unstructured":"Schwier NC, Cornelio CK, Boylan PM. A systematic review of the drug\u2013drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies. Pharmacother.\u00a02022;42:320\u2013333.","journal-title":"Pharmacotherapy"},{"key":"10563_CR40","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med.\u00a02019;381:2497\u20132505.","journal-title":"New England Journal of Medicine"},{"key":"10563_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.11622\/smedj.2013044","volume":"54","author":"IXW Goh","year":"2013","unstructured":"Goh IXW, How CH, Tavintharan S. Cytochrome P450 drug interactions with statin therapy. Singap Med J. 2013;54:131\u2013135.","journal-title":"Singapore Med J"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10563-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:02:34Z","timestamp":1789174954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10563-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10563"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10563-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}